A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in a mouse model of breast cancer. A phase I 3+3 trial was designed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2014-09, Vol.5 (18), p.8136-8146
Hauptverfasser:	Soliman, Hatem H, Jackson, Erica, Neuger, Tony, Dees, E Claire, Harvey, R Donald, Han, Hyo, Ismail-Khan, Roohi, Minton, Susan, Vahanian, Nicholas N, Link, Charles, Sullivan, Daniel M, Antonia, Scott
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravenous Administration, Oral Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - blood Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Research Paper Docetaxel Drug Administration Schedule Drug Monitoring Female Florida Humans Immunologic Factors - administration & dosage Male Maximum Tolerated Dose Middle Aged Neoplasm Metastasis Neoplasms - drug therapy Neoplasms - pathology Taxoids - administration & dosage Time Factors Treatment Outcome Tryptophan - administration & dosage Tryptophan - analogs & derivatives
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!